A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer.
- for people ages 18 years and up (full criteria)
- at UCSD
- study startedestimated completion
Bladder Cancer Bladder Tumor Muscle-Invasive Bladder Cancer immunotherapy NKTR-214 nivolumab bempeg Urinary Bladder Neoplasms Radical cystectomy (RC) Monotherapy